Candel Therapeutics (CADL) Accumulated Depreciation (2020 - 2025)

Candel Therapeutics has disclosed Accumulated Depreciation across 6 years of filings, most recently posting $3.6 million for Q4 2025.

• Accumulated Depreciation for Q4 2025 came in at $3.6 million, up 15.67% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.6 million (up 15.67% YoY), and the FY2025 annual result was $3.6 million, up 15.67% from the prior year.
• Accumulated Depreciation came in at $3.6 million for Q4 2025 at Candel Therapeutics, up from $3.4 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $3.6 million in Q2 2025 to a low of $167000.0 in Q2 2021.
• The 5-year median for Accumulated Depreciation is $1.8 million (2023), against an average of $1.9 million.
• Across the five-year window, Accumulated Depreciation jumped 383.51% in 2022 and rose 15.67% in 2025, its largest moves.
• Candel Therapeutics' Accumulated Depreciation stood at $352000.0 in 2021, then surged by 220.74% to $1.1 million in 2022, then jumped by 85.03% to $2.1 million in 2023, then soared by 47.25% to $3.1 million in 2024, then rose by 15.67% to $3.6 million in 2025.
• The last three Accumulated Depreciation figures came in at $3.6 million (Q4 2025), $3.4 million (Q3 2025), and $3.6 million (Q2 2025), per Business Quant data.